Region — International. Neutral scientific reference — not offered for sale here.

Set region

Explore Shop Tools Journal Trust

Explore  /  PNC-27

Research reference — not for sale

PNC-27

F

lead outcome

Human evidence for any indication

grades vary by outcome ↓

Peptide

also called — PNC-27 · p53-derived anticancer peptide · HDM-2-binding membranolytic peptide · INCI: none

anticancer (preclinical / contested)membranolytic peptide

Reference entry — not sold here. A p53-derived membranolytic peptide with striking but contested in-vitro anticancer claims and no human data whatsoever. No dosing published here.

In brief

PNC-27 is a synthetic peptide combining a fragment of the tumour-suppressor protein p53 with a membrane-penetrating sequence, reported by its originating groups to kill cancer cells by binding HDM-2 at the cell membrane and forming lytic pores — while sparing normal cells. The in-vitro claims are striking, but the honest picture is cautious on every axis: the data are concentrated in the originating labs, the membrane-HDM-2 selectivity premise is scientifically contested, and there are no human studies of any kind. A membranolytic (pore-forming) mechanism also carries inherent toxicity concerns. An attention-grabbing anticancer hypothesis with no human evidence behind it.

Legal standing, by region

European Union

Not approved

No marketing authorisation; research chemical only.

United States

Not FDA-approved

Not FDA-approved; not a supplement; no clinical trials registered.

International

Approved nowhere

Approved in no jurisdiction for any indication.

Evidence, by outcome

How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade

Human evidence for any indication

Marketed and discussed in research channels as an "anticancer peptide" despite a complete absence of human data. This gap is the defining fact.

None. No clinical trial of PNC-27 has been published or registered; no human pharmacokinetic, efficacy or safety data exist. · Nothing demonstrated in humans.

F

Selective cancer-cell membrane disruption (the claim)

Concentrated in the originating laboratories, mechanistically debated, and not independently established at scale. In-vitro selective lysis is a long way from a safe, effective human therapy.

In-vitro reports from the originating groups that PNC-27 binds HDM-2 expressed at the cancer-cell membrane and forms pores, lysing tumour cells while reportedly sparing normal cells. · Reported selective cytotoxicity in cell culture.

D

Mechanism (HDM-2 membrane targeting)

The membrane-HDM-2 premise is contested, and mechanism in a dish does not establish selectivity or safety in an organism.

Contains a p53 (residues 12-26) domain plus a transmembrane-penetrating sequence; proposed to target membrane-associated HDM-2 preferentially present on cancer cells. · A specific proposed mechanism.

D

Safety

A pore-forming, membrane-lysing peptide carries inherent off-target toxicity concerns; without human data, safety is entirely uncharacterised.

No human data; membranolytic mechanism · Unknown and a specific concern

—

Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for PNC-27 changes - nothing else.

The honest part

PNC-27 is the register's clearest "striking claim, absent evidence" case in oncology: dramatic in-vitro selective-lysis reports, a contested mechanism, and zero human data. The anticancer framing it is sold under is not supported by any clinical evidence, and a pore-forming peptide carries real off-target toxicity concerns. This is a research reagent surrounded by hope, not a therapy.

Identity

PNC-27 is a synthetic peptide built from two parts: a fragment of the tumour-suppressor protein p53 (residues 12-26, the HDM-2-binding domain) fused to a membrane-penetrating sequence. It is discussed in research channels as an "anticancer peptide," which makes an honest reading especially important.

Mechanism (as proposed)

The originating groups propose that PNC-27 targets HDM-2 (the human homolog of MDM2, a p53 regulator) where it is reportedly expressed at the membrane of cancer cells, and that on binding it forms pores that lyse the cell — while normal cells, said to lack membrane HDM-2, are spared. The idea is a targeted molecular knife: find a marker present on cancer-cell membranes and punch holes only there. Two cautions belong immediately alongside it: the membrane-HDM-2 selectivity premise is scientifically contested, and a pore-forming, membranolytic mechanism is inherently worrying for off-target toxicity, because lysing membranes is not a subtle action.

Reading the evidence honestly

The evidence is in-vitro and animal, concentrated in the originating laboratories, and the central selectivity claim has drawn independent skepticism. Most importantly, there are no human studies of any kind — no trial, no pharmacokinetics, no safety data. The grade is F on human evidence because the compound is presented as an anticancer agent while having none of the clinical support that framing implies. Selective tumour-cell lysis in a dish is a genuinely interesting result; it is also a claim that many compounds have made and very few have turned into safe, effective human therapies. This is a research reagent surrounded by hope, not a treatment.

Sources — 2 cited

01Michl J, Pincus MR, et al. (PNC-27 — p53-derived peptide reported to induce membranolysis of cancer cells via membrane-associated HDM-2, in-vitro and animal models.)

02Independent commentary and critiques of the membrane-HDM-2 selectivity premise.

Updated 2026-08-07 (No clinical trial registered; mechanism contested — re-check for any independent replication or human study.)

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds

Explore by goal

Longevity & cellular →

A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.

Region — International

ExploreRegister The Register — full index Categories Trust & COA How we grade Open data

ShopCosmetic peptides Journal Quizzes

TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.